Order Article Reprints

Valtonen J, Prajapati C, Cherian RM, Vanninen S, Ojala M, Leivo K, Heliö T, Koskenvuo J, Aalto-Setälä K. The Junctophilin-2 Mutation p.(Thr161Lys) Is Associated with Hypertrophic Cardiomyopathy Using Patient-Specific iPS Cardiomyocytes and Demonstrates Prolonged Action Potential and Increased Arrhythmogenicity. Biomedicines. 2023; 11(6):1558. https://doi.org/10.3390/biomedicines11061558

Valtonen, Joona, Chandra Prajapati, Reeja Maria Cherian, Sari Vanninen, Marisa Ojala, Krista Leivo, Tiina Heliö, Juha Koskenvuo, and Katriina Aalto-Setälä. 2023. "The Junctophilin-2 Mutation p.(Thr161Lys) Is Associated with Hypertrophic Cardiomyopathy Using Patient-Specific iPS Cardiomyocytes and Demonstrates Prolonged Action Potential and Increased Arrhythmogenicity" Biomedicines 11, no. 6: 1558. https://doi.org/10.3390/biomedicines11061558

Valtonen, J., Prajapati, C., Cherian, R. M., Vanninen, S., Ojala, M., Leivo, K., Heliö, T., Koskenvuo, J., & Aalto-Setälä, K. (2023). The Junctophilin-2 Mutation p.(Thr161Lys) Is Associated with Hypertrophic Cardiomyopathy Using Patient-Specific iPS Cardiomyocytes and Demonstrates Prolonged Action Potential and Increased Arrhythmogenicity. Biomedicines, 11(6), 1558. https://doi.org/10.3390/biomedicines11061558